(Q68205329)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3316565%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

title

Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3316565%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

1 reference

1 reference

1 reference

R Gold

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3316565%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

S Carpenter

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3316565%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

H Heurter

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3316565%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

M Corey

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3316565%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

H Levison

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3316565%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

language of work or name

English

0 references

publication date

1 December 1987

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3316565%20AND%20SRC:MED&resulttype=core&format=json

The Journal of Pediatrics

22 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3316565%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

volume

111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3316565%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

issue

6 Pt 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3316565%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

page(s)

907-913

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3316565%20AND%20SRC:MED&resulttype=core&format=json

The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis

22 September 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Infection in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Aureomycin therapy in the pulmonary involvement of pancreatic fibrosis (mucoviscidosis)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Treatment of pulmonary infections in patients with cystic fibrosis: A comparative study of ticarcillin and gentamicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Chemotherapy of Chronic Infections with Mucoid Pseudomonas Aeruginosa in Lower Airways of Patients with Cystic Fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Comparative study of the antibacterial activity of amikacin and tobramycin during Pseudomonas pulmonary infection in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Cefsulodin sodium therapy in cystic fibrosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Comparison of cefoperazone sodium vs methicillin, ticarcillin, and tobramycin in treatment of pulmonary exacerbations in patients with cystic fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant pseudomonas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Inhaled antibiotics in cystic fibrosis: is there a therapeutic effect?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Clinical and Bacteriological Responses to Three Antibiotic Regimens for Acute Exacerbations of Cystic Fibrosis: Tlcarcillln-Tobramycin, Azlocillin-Tobramycin, and Azlocillin-Placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Antibiotic therapy in cystic fibrosis: evaluation of clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Ceftazidime disposition in acute and stable cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Pseudomonas cepacia infection in cystic fibrosis: an emerging problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Importance of viruses and Legionella pneumophila in respiratory exacerbations of young adults with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Immediate and long-term effects of chest physiotherapy in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

7 January 2021

Imipenem/cilastatin in acute pulmonary exacerbations of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

7 January 2021

Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

7 January 2021

Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2887%2980217-2

7 January 2021

10.1016/S0022-3476(87)80217-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3316565%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

1 reference